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Background
P. multocida is a Gram-negative pathogen responsible for
causing disease in animals of economic significance to
livestock industries throughout the world. It is the causa-
tive agent of numerous diseases in animals including fowl
cholera in avian species, hemorrhagic septicaemia in
ungulates and atrophic rhinitis in swine. Current vaccines
include bacterins, which only provide limited protection
against homologous serotypes and live attenuated strains,
which have been observed to revert to virulence. Therefore
there is a need for more effective vaccines to control dis-
eases caused by P. multocida.
As a step towards developing protective vaccines against
fowl cholera, a genomics based approach was applied to
the identification of putative vaccine antigens. This
approach utilised a bioinformatics analysis of the P. mul-
tocida genome sequence using several types of algorithms
(eg. PSORTB) to select candidate genes according to their
vaccine potential, based on their predicted sub-cellular
location (outer membrane or secreted) and their similar-
ity to other proteins with putative or confirmed experi-
mental roles in infection and immunity as well as
expression analysis based on microarray studies. The bio-
informatics-based predictions were complemented by a
comprehensive proteomics analysis of the P. multocida
outer membrane to identify highly expressed membrane
associated proteins.
Results
Over 130 P. multocida proteins were predicted to be sur-
face exposed and/or secreted extracellularly, thus necessi-
tating the adoption of a high-throughput cloning strategy.
A GatewayTM (Invitrogen) cloning and expression system
was used to clone PCR-amplified P. multocida ORFs. The
forward primers were designed to include the sequence 5'-
CACCATG required for directional topoisomerase clon-
ing, as well as the addition of an ATG initiation codon.
PCR primers were designed so as to amplify the region
that encompasses the entire coding sequence for the sub-
unit but does not include the sequence encoding the sig-
nal peptide. As the genes were to be expressed in frame
with a C-terminal tag the native stop codon was removed
when designing the reverse primers. The PCR products
were cloned into the Gateway entry vector pENTR/SD/D-
TOPO® (Invitrogen). A sample of the PCR products is
shown in Figure 1, panel A.
After the target genes were verified by sequencing and
restriction digestion analysis, they were transferred by
recombination (LR Clonase kit – Invitrogen) from the
entry clone to the Invitrogen destination vector pBAD-
DEST49TM to allow subsequent expression of C-terminal
fusions of the expressed proteins. A sample of an expres-
sion screening of 14 clones is shown in Figure 1, panel B.
80% of target clones showed positive expression (target
clones are fused to an N-terminal Thioredoxin His-Patch
as well as a C-terminal His-tag).
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insoluble. Expression at different temperatures as well as
the transfer of 20 targets into an N-terminal GST vector
did not enhance solubility. These expressed proteins are
currently being purified as insoluble inclusion bodies (see
Figure 1, panel C). The induced cultures were chemically
lysed by incubation of the culture with PopCulture
(Novagen), benzoase and lysozyme for 20 min at 20°C 1
ml of the cell lysate was then added to a 96-well filter plate
and the solution was drawn through the filter under vac-
uum. The insoluble inclusion bodies were retained while
soluble proteins passed through the filter. The retained
inclusion bodies were washed once to remove any
remaining soluble proteins. The inclusion bodies were
then denatured by the addition of 200 μl of 8 M urea to
each corresponding well, incubated for 16 h at 4°C and
collected under vacuum.
Approximately 25 μg of each antigen were injected subcu-
taneously into 5 mice followed by a booster injection
using aluminium hydroxide as an adjuvant. Antisera were
raised against 18 antigens. Immunoblot analysis was per-
formed with cell lysates prepared from different strains of
P. multocida and probed with polyclonal antiserum spe-
cific for PM1578, which recognised the native P. multocida
protein. PM1578 was absent in strains harbouring a muta-
tion in pm1578 (see Figure 1, panel D). Antisera raised
against 8 of the 18 antigens injected into mice recognised
the corresponding wild-type proteins (data not shown).
To evaluate expression of Gateway cloned antigens from
P. multocida X-73 during infection in the chicken host,
convalescent-phase sera from three infected chickens were
tested for reactivity against all the recombinant proteins
using Western blot analysis. The results demonstrated that
immune sera generated during P. multocida infection rec-
ognised a total of 23 recombinant proteins (data not
shown).
Conclusion and future development
Gateway cloning system provides a highly efficient
method to generate plasmids harbouring genes from P.
mutlocida X-73 and for the generation of expression
clones.
In silico analysis identified 130 membrane associated and
secreted proteins, 114 of which have been successfully
cloned into a Gateway entry vector. Out of these 114 entry
clones, 92 were transferred to a Gateway expression vec-
tor. Of these, 80% were shown to express measurable lev-
els of protein in E. coli.
Because of the relatively poor efficiency of recovering sol-
uble proteins tagged with the thioredoxin tag, efforts are
underway to express the target proteins in different expres-
Different P. multocida strains pm1578 mutantFigu  1
Different P. multocida strains pm1578 mutant. Shown 
are (A) PCR amplification of P. multocida vaccine target ORFs 
for Gateway cloning. (B) SDS-PAGE and Coomassie Blue 
staining of crude lysates expressing P. multocida X-73 
recombinant proteins in E. coli DH5α. All cultures were 
induced with arabinose at mid-log phase (C) Isolation of tar-
get proteins from inclusion bodies. Coomassie Blue staining 
of 14 recombinant proteins solubilised in 8 M Urea. (D) Pro-
teins in lysates were separated by electrophoresis and the 
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sion systems. To address this hurdle and as means of pref-
erably obtaining correctly folded proteins for vaccine and
functional studies, preliminary attempts to express genes
as recombinant proteins in NusA fusion expression con-
structs resulted in significant improvement.Page 3 of 3
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